Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/CD22 CAR-T for CD19+ ALL
NCT04303520Phase 1Unknown
- Start
- May 2018
- Primary completion
- Sep 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD19/CD22 CAR-T cells in acute lymphoblastic leukemia (ALL). Primary endpoint: Occurrence of study related adverse effects at 6 months. Status: unknown.
02
Drugs
anti-CD19/CD22 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04303520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303520.